Novel Nanotechnology Based Delivery Systems for Chemotherapy and Prophylaxis of Tuberculosis
| Autor: | Rajesh Jain, Isha Naik, Kapil Punjabi, Jinesh Maniar, Shashikant Vaidya, Mala D Menon, Hemali Savla |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Drug
Chemotherapy Tuberculosis Communicable disease biology business.industry medicine.medical_treatment media_common.quotation_subject Nanotechnology Drug resistance medicine.disease biology.organism_classification Mycobacterium tuberculosis Infectious disease (medical specialty) Medicine business Dosing Frequency media_common |
| DOI: | 10.1016/b978-0-12-813351-4.00034-1 |
| Popis: | Tuberculosis (TB), a serious infectious disease caused by Mycobacterium tuberculosis , has resulted in more deaths than any other communicable disease, and has caused a lot of problems in the economy and social status of developing countries. Current chemotherapy for TB still relies on drugs discovered way back in the 1960s and is laborious, extensive, and remains extremely complicated to complete in many of the highest burdened regions. The various global strategies like DOTS therapy have not achieved much success, and the Third World is plagued with the development of drug-resistant strains. With difficulties in obtaining novel anti-TB drug candidates in the development pipeline, it is important to look into the existing drugs and develop novel and targeted delivery systems of these drugs, to overcome the drawbacks of current conventional formulations. Nanoparticle (NP) technology offers an attractive and promising approach to take the existing chemotherapies and deliver them more efficaciously, reducing the dosing frequency and duration of treatment, as well as increased bioavailability. In addition, it is possible to functionalize the NPs with specific ligands and achieve active targeting to the Mycobacterium -infested tissues, especially the alveolar macrophages. This advance can help achieve quicker cures, with lower doses, improved patient adherence, and overall reduce medication burden; all of which can help curb the development of drug resistance. Further, several nanotechnology-based vaccines as an alternative to the current bacilli Calmette–Guerin vaccine for prevention of TB are also promising approaches being investigated. This chapter will provide an insight into the nanotechnology approaches for chemotherapy and prophylaxis of TB, and highlight the challenges in implementation of these technologies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|